Table 5. Comparison of the ratios of circulating RAS peptides in ARDS at study entry.
| *Ratio: Precursor→Product | Median Ratio (interquartile Range) | ||
|---|---|---|---|
| Non-survivors | Survivors | P-value | |
| A(1–12)→A(1–10) | 60.0 (2.05–315.99) | 4.05 (0.89–29.93) | <0.001 |
| A(1–10)→A(1–9) | 0.08 (0.04–0.27) | 1.00 (0.51–2.05) | <0.001 |
| A(1–10)→A(1–8) | 0.06 (0.01-.11) | 0.74 (0.39–1.09) | <0.001 |
| A(1–9)→A(1–7) | 0.27 (0.04–1.09) | 0.4 (0.09–0.64) | 0.692 |
| A(1–10)→A(1–7) | 0.03 (0.01–0.08) | 0.48 (0.14–0.97) | <0.001 |
| A(1–8)→A(1–7) | 0.63 (0.24–1.82) | 0.85 (0.46–1.07) | 0.655 |
| A(1–8)→A(2–8) | 5.8 (0.77–16) | 1.54 (0.55–4.93) | 0.093 |
| A(1–7)→A(1–5) | 1.00 (0.27–2.6) | 0.29 (0.08–2.44) | 0.070 |
| A(1–7)→aA(1–7) | 1.18 (0.37–9.12) | 2.12 (0.91–4.85) | 0.206 |
| A(2–8)→A(3–8) | 0.26 (0.10–0.93) | 0.63 (0.14–1.00) | 0.438 |
These ratios of product to precursor provide insights into the metabolic levels of the catalyzing enzymes. Ratios significantly different between survivor and non-survivor groups were A(1–12) →A(1–10), A(1–10) →A(1–9), A(1–10) →A(1–8) and A(1–10) → A(1–7) (p <0.001)
*Ratio is calculated as product concentration/precursor concentration.